AbCellera Biologics Inc. shares rose to a 52-week high of $12.15 on Tuesday, extending a rally that has delivered a 172.54% gain over the past 12 months. The biotech’s stock has surged 232.6% in the last six months and 210.23% year-to-date, driven by clinical progress and a fresh capital raise.
The company reported adjusted losses of $0.18 per share in the second quarter of 2026, wider than the expected $0.17 loss, while revenue totaled $4.1 million, below the anticipated $8.1 million. AbCellera also announced a $200 million underwritten public offering of common stock, with proceeds to be used for general corporate purposes.
Clinical developments supported the advance. ABCL635, an investigational treatment for vasomotor symptoms, met its primary efficacy endpoints in a Phase 2 trial, reinforcing the program’s potential. Truist Securities raised its price target on the stock to $30 from $12 and maintained a Buy rating, citing peak risk-adjusted sales estimates of $1.1 billion for the program.
Market observers, however, flagged valuation concerns. InvestingPro analysis described the shares as among the most overvalued relative to fair value, while its Relative Strength Index suggested the stock was in overbought territory. Analysts do not expect the company to achieve profitability in 2026.
